GlassScriptPhysician profile
William Thomas Mcgarry
NPI 1760486005
$13,010.09
in general payments reported to CMS, 2019-2025
63 companies · $4,441 in 2025
The $4,441 reported for 2025 was more than what 80% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.09 · 2020: $29.11 · 2021: $319 · 2022: $940 · 2023: $3,148 · 2024: $4,036 · 2025: $4,441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,427.63 |
| Education | $197.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,396.70 | 2021-2025 | Enhertu, Imfinzi, Lynparza |
| Merck Sharp & Dohme LLC | $942.33 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $927.20 | 2019-2025 | Piqray, Kisqali |
| Pfizer INC. | $782.93 | 2022-2025 | |
| Abbvie INC. | $717.65 | 2021-2025 | |
| Celgene Corporation | $672.42 | 2021-2025 | Reblozyl, Pomalyst, Opdualag |
| Janssen Biotech, INC. | $517.27 | 2021-2025 | Darzalex, Tecvayli, Talvey |
| Glaxosmithkline, LLC. | $466.36 | 2022-2025 | Zejula, Jemperli, Ojjaara |
| Incyte Corporation | $401.42 | 2023-2025 | Jakafi, Monjuvi, Pemazyre |
| E.R. Squibb & Sons, L.L.C. | $391.92 | 2019-2025 | Opdivo, Augtyro, Opdualag |
| Seagen INC. | $328.91 | 2023-2025 | Adcetris, Tivdak, Padcev |
| Eisai INC. | $302.52 | 2022-2025 | |
| Daiichi Sankyo INC. | $300.78 | 2021-2025 | Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $294.91 | 2023-2025 | Fruzaqla, Ninlaro, Iclusig |
| Array Biopharma INC | $285.05 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $243.83 | 2023-2024 | Myrisk |
| Lilly USA, LLC | $237.40 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Bayer Healthcare Pharmaceuticals INC. | $234.95 | 2024-2025 | |
| Gilead Sciences, INC. | $234.63 | 2023-2025 | Trodelvy |
| Axonics, INC. | $229.87 | 2023 | Axonics |
| Astellas Pharma US INC | $213.82 | 2019-2025 | Vyloy, Xospata, Xtandi |
| Kite Pharma, INC. | $162.88 | 2023-2025 | Yescarta |
| Pharmacyclics LLC, An Abbvie Company | $147.24 | 2021-2023 | Imbruvica, Epkinly |
| Beigene USA, INC. | $144.64 | 2021-2024 | Brukinsa |
| Dendreon Pharmaceuticals LLC | $139.91 | 2024-2025 | Provenge |
| Regeneron Healthcare Solutions, INC. | $138.41 | 2021-2025 | Libtayo |
| Stemline Therapeutics INC. | $133.79 | 2023-2025 | Orserdu, Elzonris |
| Genentech USA, INC. | $133.63 | 2022-2025 | Polivy, Venclexta, Tecentriq |
| Amgen INC. | $114.76 | 2022-2023 | Kyprolis, Nplate, Xgeva |
| Tersera Therapeutics LLC | $110.21 | 2023-2025 | Zoladex |
| Karyopharm Therapeutics INC. | $96.50 | 2023-2025 | Xpovio |
| Genzyme Corporation | $92.24 | 2021-2024 | |
| Mirati Therapeutics, INC. | $90.99 | 2023-2024 | Krazati |
| Aveo Pharmaceuticals, INC. | $81.56 | 2022-2025 | |
| Pharmacosmos Therapeutics INC. | $79.80 | 2022-2024 | Cosela, Monoferric |
| Alexion Pharmaceuticals, INC. | $77.82 | 2021-2024 | Ultomiris |
| Ipsen Biopharmaceuticals, INC | $73.39 | 2022-2024 | Onivyde |
| Sumitomo Pharma America, INC. | $68.21 | 2024-2025 | Orgovyx |
| Sobi, INC | $66.45 | 2024-2025 | |
| Deciphera Pharmaceuticals INC. | $66.01 | 2023-2025 | Qinlock, Tgct |
| Jazz Pharmaceuticals INC. | $64.64 | 2024-2025 | |
| Exelixis INC. | $63.29 | 2023-2025 | Cabometyx |
| Legend Biotech USA INC. | $62.57 | 2025 | Carvykti |
| Beone Medicines USA, INC. | $59.76 | 2025 | Brukinsa |
| Emd Serono, INC. | $55.62 | 2024-2025 | |
| Pharmaessentia USA Corporation | $54.37 | 2024-2025 | Besremi |
| Adc Therapeutics America, INC. | $46.01 | 2024 | |
| Biocon Biologics INC | $45.85 | 2024 | Fulphila, Ogivri |
| Recordati_rare_diseases_inc. | $39.65 | 2024-2025 | Enjaymo, Sylvant |
| Kyowa Kirin, INC. | $39.21 | 2023 | Poteligeo |
| Blueprint Medicines Corporation | $37.30 | 2023-2024 | Ayvakit |
| Taiho Oncology, INC. | $36.41 | 2024-2025 | |
| Agios Pharmaceuticals, INC. | $31.83 | 2023-2024 | Pyrukynd |
| Springworks Therapeutics, INC. | $30.79 | 2024-2025 | Ogsiveo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.42 | 2025 | |
| Servier Pharmaceuticals LLC | $24.98 | 2023 | |
| Azurity Pharmaceuticals, INC. | $24.09 | 2025 | Danziten |
| Cti Biopharma Corp. | $23.22 | 2023 | Vonjo |
| Geron Corporation | $23.00 | 2025 | Rytelo |
| Sun Pharmaceutical Industries INC. | $21.35 | 2022 | |
| Alnylam Pharmaceuticals INC. | $20.92 | 2022 | |
| Rigel Pharmaceuticals, INC. | $18.86 | 2025 | Rezlidhia, Tavalisse, Gavreto |
| Progenics Pharmaceuticals, INC. | $14.64 | 2023 | Pylarify |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Mcgarry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.